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Abstract
To examine whether the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is altered in the
endothelial cells in response to glucose and the significance of such alteration. We incubated human umbilical vein endothelial cells with media
containing various glucose levels. We found an increase in MALAT1 expression peaking after 12 hrs of incubation in high glucose. This increase
was associated with parallel increase in serum amyloid antigen 3 (SAA3), an inflammatory ligand and target of MALAT1 and was further accompanied by increase in mRNAs and proteins of inflammatory mediators, tumour necrosis factor alpha (TNF-a) and interleukin 6 (IL-6). Renal tissue from the diabetic animals showed similar changes. Such cellular alterations were prevented following MALAT1 specific siRNA transfection.
Results of this study indicate that LncRNA MALAT1 regulates glucose-induced up-regulation of inflammatory mediators IL-6 and TNF-a through
activation of SAA3. Identification of such novel mechanism may lead to the development of RNA-based therapeutics targeting MALAT1 for diabetes-induced micro and macro vascular complications.

Keywords: endothelial cells  MALAT1  IL6  TNFa  kidney  diabetes  glucose

Introduction
Diabetes is a surging epidemic not only in North America but also
worldwide. Among the diabetes-induced complications, retinopathy,
nephropathy, cardiomyopathy, neuropathy and atherosclerosis,
causing stroke and myocardial infractions are considered to be the
major causes of morbidity and mortality in the diabetic population
[1–3]. The macro and micro vascular affections are key features of
such complications. Endothelium is a major component of the vascular bed and one of the key cell type affected by glucose [1–3]. As
endothelium forms a protective barrier for all major organs in the
body, maintaining endothelial homeostasis is essential for physiological organ function [1]. Under conditions of nutrient excess, such as
diabetes, endothelial insult leads to overproduction of specific cytokines causing an inflammation-like condition. Hence, understanding
the molecular mechanisms causing endothelial inflammation would
help prevent endothelial as well as end organ damage in diabetes [1,
2]. Several molecules have been identified as the major initiators
and mediators of inflammation [1, 3]. Here, we reveal role for
metastasis associated lung adenocarcinoma transcript1 (MALAT1), a
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6.5 Kb nuclear residing long non-protein coding RNA, in hyperglycaemia induced endothelial damage. MALAT1 was originally shown to
control of tumour metastasis and cancer cell survival [4]. MALAT1
executes such functions by its ability to inhibit tumour cell death
through induction of proteins like Bax, Bcl-2 and P53 [5, 6]. These
molecules are involved in cell cycle progression, vascularization and
angiogenesis. However, specific mechanism(s) through which this
non-protein coding RNA mediates downstream effects remains
unidentified. Specifically, MALAT1’s roles in noncancerous cells subjected to metabolic or nutrient stress haven’t been investigated in
depth.
Recently, MALAT1 has been identified as a regulator of inflammatory cytokine production in other systems [7]. Study conducted by
Yan et al. was first to show MALAT1 alteration in the retina in diabetes [8]. Here, we investigated whether MALAT1 regulates inflammatory pathways involving inflammatory cytokines in diabetes.
Along with interleukin 6 (IL-6) and tumour necrosis factor alpha
(TNF-a), we investigated mechanisms by which MALAT1 may regulate these cytokines through serum amyloid antigen (SAA). We further expanded these studies in vivo. Although both in type 1 and in
type 2 diabetes, production of inflammatory cytokines such as SAA,
IL-6 and TNF-a have been shown to play important roles, no studies
have previously been performed exploring the transcriptional mechanisms, specifically with respect to that of the role of long non-coding
RNAs (lncRNA), in glucose-induced endothelial damage [3, 9]. In this
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study, we have tried to identify whether in endothelial cells (i) glucose
alters lncRNA, MALAT1, (ii) whether such alteration has functional
significance, i.e. associated with regulation of downstream inflammatory mediators and (iii) whether changing MALAT1 expression corrects glucose-induced inflammatory cascades.

Materials and methods
Cell culture and reagents

Real time quantitative PCR

Human umbilical vein endothelial cells (HUVECs) were obtained from
Lonza (Canada Missisauga, ON) and were cultured in endothelial basal
medium – 2. This medium was supplemented with the required growth
factors (Lonza –growth factor Kit) and 5% foetal bovine serum. Following overnight serum starvation cells were incubated with 5 mM D-glucose (NG) or 25 mM D-Glucose (HG) or 25 mM L-Glucose (LG, osmotic
control) or with other reagents as specified.

Animal studies
All animal studies, were approved by the Western University Council on
Animal Care Committee. The experiments were performed in accordance
to The Guide for the Care and Use of Laboratory Animals (NIH guidelines, revised in 1996). Animals were made diabetic using Streptozotocin dissolved in citrate buffer maintained at a low acidic pH (70 mg/kg

RNA was extracted using TRizolTM reagent (Invitrogen, burlington, ON,
Canada). In brief, following Trizol treatment, chloroform was added to
the cell lysate and the samples were centrifuged at 12,000 9 g for
15 min. This was followed by subsequent treatment with isopropanol
and wash with ethanol with centrifugation. Collected pellets were treated
with RNAse free water. Following concentration determination by UV
spectrophotometry, 2 lg of total RNA was used to make cDNA using
reverse transcription kit from Applied Biosystems Inc, USA. The levels
of target gene and house-keeping gene (18SRNA, Grand Island a widely
used stable internal reference gene) were measured using a SYBR green
dye in a light cycler (Roche Diagnostics, PQ). The primer sequences for
human MALAT1 are forward primer Laval – CTTAAGCGCAGCGCCATTTT,
reverse primer CCTCCAAAC CCCAAGACCAA, human SAA3 – forward
primer CTGGGTCACTGCTCC TCTTC, reverse primer ACTAGCACC
TTTGCCCAGTG. Predesigned human TNF-a [Quantitech primer
HS_TNF_3_SG (Cat no-QT01079561)] and human IL-6 [Quantitech

B

A
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of mice, IP injection X3 on alternate days), non-diabetic (Control) animals were given the Citrate buffer alone. After the third dose of injection, hyperglycaemia was monitored using Freestyle Freedom Lite blood
glucose monitoring system (Abbott Diabetes Care, Saint-Laurent, QC,
Canada). Diabetic animals were maintained in hyperglycaemic state for
2 months on a standard rodent diet with water ad libitum. The animals
were monitored regularly for blood glucose and body weight. At the end
of 2 months, the animals were killed, kidneys were isolated and frozen
for future use.

D

E

Fig. 1 Hyperglycaemia induces SAA 3 gene expression and protein production in the endothelial cells through long non-coding RNA MALAT1. Endothelial cells were exposed to media containing normal (NG, 5 mM) and high D-glucose (HG, 25 mM) concentrations for various durations. RNA
analyses by RT-PCR (mean  S.E.) showed increase in (A) MALAT1 expression peaking at 12 hrs, but not when the cells were incubated with
25 mM of L-glucose (LG, osmotic control) in association with (B) increased SAA3 expression. (C) MALAT specific siRNA transfection (Si) caused
significant reduction in basal- and glucose-induced MALAT1 up-regulation. Such knockdown of MALAT1 further normalized basal- and glucoseinduced (D) SAA3 mRNA and (E) protein expression. [RNA data are expressed as a ratio to 18sRNA (mean  S.E.), normalized to controls, n = 3
or more per groups, *: significantly different from corresponding NG, #: significantly different from corresponding HG, Sc: scrambled siRNA].
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Fig. 2 Hyperglycaemia regulates expression inflammatory genes IL-6 and TNF-a
through MALAT1 in endothelial cells. (A)
HUVEC were treated with normal (NG,
5 mM) and high glucose (HG, 25 mM)
and were transfected with siRNA for MALAT1 (Si) and scrambled control (Sc).
Such siRNA transfection reduced both
basal- and glucose-induced up-regulation
of (A) IL-6 and (B) TNF-a mRNAs, (C) IL6 protein and (D) TNF-a protein [mRNA
data are expressed as a ratio to 18sRNA
and all data (mean  S.E.) are normalized
to controls, *: significantly different from
corresponding NG, #: significantly different from corresponding high glucose
groups, n = 3 or more per group].
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primer HS_IL-6_1_SG (Cat no-QT00083720)] were obtained from Qiagen (Toronto, ON, Canada).

ELISA assay
Following isolation of proteins from the endothelial cells using radioimmunoprecipitation assay buffer, protein concentrations were measured
using BCA protein assay kit (Pierce, Rockford, IL, USA). Equal concentrations and amounts of total protein lysates from treatment groups
were used each For ELISA. Human SAA 3 (cat no. CSB E11836h) kit
was obtained from Cusabio-Biotech Co. Wuhan, Hubei, China For
human TNF-a and human IL-6, ELISA kits (cat no. DTA00C and D6050
respectively) from R&D Systems (Mineapolis, MN, USA) were used.
Following the treatments and incubation procedures as suggested by
the vendors, the samples were read at 450 nm and background corrected at 568 nm.

Intracellular ROS measurement
After the HUVEC cells have reached 75% confluence, they were subjected
to transfection and were exposed to normal and high glucose conditions in
a serum free medium. Following 12 hrs of high or low glucose incubation,
the cells were exposed to 20 ,70 -dichlorofluorescein diacetate in required
concentrations for 20–30 min. The reactive oxygen species levels were
read by the fluorescence, emitted by the cell permeable dye converted to
20 ,70 -dichlorofluorescein after being reacted with intracellular reactive oxygen species. The excitation and emission wavelengths were 492 and
521 nm respectively.

Chemicals and reagents
All chemicals, unless otherwise specified, were obtained from Sigma
Chemicals, Oakville, ON Canada.

SiRNA transfection

Statistical analysis

SiRNAs targeted against human MALAT1 (product ID, nos’. 272231,
272233) were obtained from Life Technologies. In brief, all experimental
groups were replenished with serum, growth factor and antibiotics free
medium overnight. The cells were then either treated with SiRNA for
human MALAT1 or the scrambled SiRNA (product ID, AM4635; Life
Technologies) in Lipofectamine 2000 transfection reagent (Invitrogen)
following protocols provided by the vendors. Following initial assessments, we found that although both are effective, no. 272231 was
slightly more robust (although both reduced MALAT1 RNA ~65%; no.
272231 reduced SAA3 mRNA expression ~50%, compared to ~62% by
no. 272233). Hence, in the subsequent experiments no. 272231 was
used as MALAT1siRNA. For SiRNA for SAA we used SAA SiRNA (h)
which is non-specific but targets SAA1, SAA2 and SAA3 (Santa Cruz
Biotechnology, USA). We also used a second siRNA (cat no. AM16708;
Life Technologies Santa Cruz, CA). Following a similar strategy as
above, we used siRNA from Santa Cruz for subsequent experiments.
Following transfection the cells were exposed to various treatments and
were used for RT-qPCR and ELISA as above.

All experiments were performed in triplicate at least 3–5 times. The data
are expressed as means  S.E.M. Significance were determined using
ANOVA and/or Student’s t-test with post hoc analysis using Graph Pad
Prism software (La Jolla, CA, USA). The differences between groups
were considered significant at the level of P < 0.05.
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Results
Glucose stimulates early induction of MALAT1 in
endothelial cells
As endothelial cells are primary targets of glucose-induced damage,
we investigated such changes in well-characterized HUVECs. Here,
we found that 25 mM glucose (HG) up-regulates MALAT1 RNA
expression compared to 5 mM glucose (NG). We found >2-fold
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increase MALAT1 expression levels after 6 hrs of incubation with HG,
reaching to a peak of >5-fold increase after 12 hrs (Fig. 1A). No such
changes were seen with 25 mM L-glucose (osmotic control, Fig. 1A).

MALAT1 regulates inflammatory ligand
expression in hyperglycaemia
Zhang et al. have shown that MALAT1 is dispensable for growth,
development and survival under a normal physiological setting [4]. In
addition, they demonstrated that SAA3, a regulator of inflammatory
cascade is a direct target of MALAT1. SAA3 is further diminished in
the MALAT1 KO mice [4]. In our study, incubation of endothelial cells
in high glucose caused increase in SAA3 expression peaking at
12 hrs (Fig. 1B), in association with increased MALAT1. We used
siRNA to demonstrate a direct relationship both in low and high glucose conditions. Such siRNA transfection lead to >60% reduction in
MALAT1 RNA in NG and lead to a significant drop in SAA3 expression
(Fig. 1C and D). Furthermore, such transfection of HUVECs in HG
normalized glucose-induced increase in MALAT1 RNA and SAA3
mRNA expression (Fig. 1C and D). We further examined SAA3 protein
levels both in NG and HG conditions with or without SiRNA transfection. As expected, glucose-induced ~2.5-fold increase in SAA3 protein, was normalized to control levels following siRNA knock down of
MALAT1 in HG (Fig. 1E). These data confirm that MALAT1 is a direct
regulator of inflammatory ligand, SAA3, both under basal and under
hyperglycaemic condition.

even in the presence of MALAT1 SiRNA. However, when SAA was
silenced, we were able to bring down that drastic increase in IL-6
mRNA and TNF mRNA significantly (Fig. 3) but could nt normalize to
the control levels. These findings suggest that there are other pathways, in addition to the MALAT1-SAA axis may also be playing a role
following hyperglycaemic stress.

The early induction of MALAT1 in
hyperglycaemia is not evident at later timepoints and inflammatory cytokines follow similar
pattern
The early induction of MALAT1 RNA, seen following high glucose
incubation of HUVECs was not apparent at 24, 48 or 72 hrs,

A

MALAT1 inhibition attenuates the inflammatory
response seen in hyperglycaemia
B

Results from the previous studies have shown that SAA3 augments
transcription of IL-6 and TNF-a with subsequent increase in the signalling of these classic inflammatory markers [9] in mice models.
SAA 3 was considered a pseudogene in humans, till Larson et al., first
showed that SAA 3 is regulated by prolactin and LPS in human mammary gland epithelial cells [10]. Hence, we examined whether glucose-induced increased human SAA3 carries out similar downstream
functions. In keeping with such notion, following 12 hrs of HG incubation, when the increase in MALAT1 and SAA3 reached the peak,
there were augmented expression of mRNA and protein of IL-6 and
TNF-a (Fig. 2). Furthermore, siRNA mediated gene silencing of
MALAT1 also showed reduction in IL-6 and TNF-a mRNA and protein
levels confirming a direct regulatory relationship (Fig. 2).

MALAT1 induced inflammatory cascade is
significantly regulated by SAA
To examine whether hyperglycaemia induced inflammatory markers
induction by MALAT1 requires SAA, we tried silencing MALAT1 and
added Apo–SAA, a recombinant protein. Addition of Apo SAA further
aggravated the cytokine induction than high glucose alone at 12 hrs

Fig. 3 MALAT1 induced regulation of cytokine induction occurs mostly
through SAA. HUVECs, treated with 5 mM glucose (NG) or 25 mM glucose (HG), were transfected with siRNA for MALAT1 and scrambled
siRNA (SCr) used as control. Apo-SAA, a recombinant peptide, was
used to stimulate SAA pathways and bring about downstream effects.
(A) IL-6 and (B) TNF-a MRNAs were measured at 24 hrs time-point in
the presence and absence of MALAT1 silencing. [mRNA data are
expressed as a ratio to 18sRNA and all data (mean  S.E.) are normalized to controls, n = 3 or more per group, *: significantly different from
control and @: significantly different from Apo SAA treated groups with
MALATSi, SAA Si: SAA3 siRNA].
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Fig. 4 The effect of hyperglycaemia on MALAT1, IL-6 and TNF-a at later time-points. HUVECs incubated with 5 mM (NG) and 25 mM glucose (HG)
showed (A) no significant alteration of MALAT1mRNA (measured by RT-PCR) expression after 24, 48 or 72 hrs. (B) IL-6 and TNF-a mRNA (measured by RT-PCR) and protein expressions (measured using ELISA) were increased following HG incubation at 48 hrs, but (C) returned to NG levels
after 72 hrs of incubation [mRNA data are expressed as a ratio to 18sRNA and all data (mean  S.E.) are normalized to controls, n = 3 or more
per group, *: significantly different than control and P < 0.05, AU: arbitrary units of protein].

compared to normal glucose (Fig. 4A). It is possible that, either MALAT1 has a shorter half-life or their stability is influenced by hyperglycaemia at a longer time period. It is also possible that following
initiation, other glucose-induced counter-regulatory mechanisms
come into place. Interestingly, analysis of mRNA expressions of IL-6
and TNF-a at 48 hrs showed a sustained increase even when MALAT1 mRNA expression was normalized as shown in Figure 4. However, in spite of an initial rise at 12 hrs time-point following
hyperglycaemia (approximately 2.5-fold for both these transcripts), at
48 hrs the level of such up-regulations were lower (1.5- and 2-fold
increase for IL-6 and TNF-a respectively). It could be possible that
even though the stimulus by MALAT1 had subsided, the cytokines
(IL-6 and TNF-a) could turn on their own gene and cause their mutual
induction through a positive feedback loop. Even the protein expressions of IL-6 and TNF-a were high at this point, IL-6 protein was
maintained at almost at the same level when we compared the fold
change at 12 and 48 hrs protein levels. The early rise (12 hrs) in
TNF-a protein (almost 2.5-fold) was reduced at 48 hrs (almost 1.5fold) time-point. These findings may suggest that IL-6 and TNF-a
may not be direct targets of MALAT1 and such regulations are mediated through downstream molecules, in this case SAA, thus prolong1422

ing the effects. However, exact cause(s) for this rise and fall of
MALAT1 and downstream mechanisms remain to be identified and
needs specific experiments, which are beyond the scope of this
study.

MALAT1 is increased in the kidneys of mice with
diabetes
To examine whether such changes are of relevance in vivo, we
analysed kidneys from streptozotocin induced diabetic mice and
age-and sex-matched controls after 2 months of follow-up. As
endothelial cells, lining the renal microvasculature are one of the
first cell type exposed to the hyperglycaemic milieu, we thought
that kidneys are good targets for analysing the inflammatory effects
of hyperglycaemia. Diabetic mice were hyperglycaemic (diabetic
mice 22.2  3.6 mmol/l versus controls 6.8  0.8 mmol/l,
P < 0.001) polyuric and showed lower bodyweight (diabetic mice
23.5  0.90 g versus controls 32.1  3.6 g, P < 0.001). We saw
a significant increase in MALAT1 RNA expression and a moderate
increase in SAA3 mRNA expression (almost ~20%) compared to
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Fig. 5 MALAT1 expression is up-regulated
in the kidneys of diabetic mice. Streptozotocin induced diabetic mice maintained in
the hyperglycaemic state for 2 months
showed increased mRNA expression of
both (A) MALAT1 and (B) SAA 3. Such
increases were associated with (C) TNF-a
and (D) IL-6 mRNA up-regulation (data
are expressed as mean  S.E., expressed
as a ratio to 18sRNA, normalized to controls, n = 4–5/group, *: P < 0.05).

A

C

B

D

the controls. Such changes were associated with increased IL-6
and TNF-a mRNA levels in diabetes (Fig. 5).

MALAT1 silencing dampens the early rise in
oxidative stress
We were interested in finding out whether early inhibition of MALAT1
(at 12 hrs) has functional significance in endothelium. Glucoseinduced oxidative stress is a key alteration in the endothelial cells and
is a mediator of most, if not all, other downstream effects [11].
Hence, we measure oxidative stress as a functional indicator. We
silenced MALAT1 and compared the ROS generation following hyper-

Fig. 6 Effect of MALAT1 inhibition of endothelial ROS levels. In the
endothelial cells, 25 mM glucose (HG) glucose-induced increased ROS
production was prevented following MALAT1 SiRNA transfection (SiMALAT1) but not by scrambled siRNA (Scr) transfection (NG = 5 mM glucose, the data are mean  S.E., n = 3 or more/group, n = 3 or more
per groups, *: significantly different from NG-Scr, #: significantly different from HG-Scr, AU: arbitrary units).

glycaemic stress at 12 hrs. We found a 4.5-fold increase in ROS production in high glucose condition, which was attenuated following
MALAT1 silencing (Fig. 6).

Discussion
In this study we have shown that lncRNA MALAT1 is induced following short-term hyperglycaemia which turns on early inflammatory
events in the endothelium through SAA3. Although the ability of hyperglycaemia to induce inflammatory markers has been previously
studied, mechanistic role of a non-coding RNA to mediate such process has not been identified previously.
In a chronic disease like diabetes, low grade inflammatory
changes associated with increased production of inflammatory mediators may be a key mechanism in the pathogenesis of chronic diabetic complications [12]. Glucose-induced oxidative DNA damage
may trigger increased expression of specific cytokines causing tissue
damage. Here, we have identified a novel mechanism which may play
a key role in such process at the transcriptional level. Identification of
such process further opens up the possibilities of novel therapies targeting specific RNA molecules. It is well known that only 1.5% of the
entire genome has protein-coding capacity [13, 14]. Non-protein
coding RNAs are probably of importance and relevance in normal
development and in various diseases through their capacity to regulate transcription and translation [13, 14]. Hence, they constitute
potential drug targets capable of producing phenotypic changes. The
specific roles of most of these lncRNAs remain mysterious although
they are known to play regulatory roles in various, if not all, biological
processes [13, 14]. MALAT1 (AKA NEAT2: noncoding nuclearenriched abundant transcript 2, HCN, LINC000 47) is a large, infrequently spliced non-coding RNA, which is highly conserved. MALAT1
is expressed in the nucleus and was originally described to regulate
metastasis and cell motility [4]. MALAT1 is now known to be of
importance in other disease processes [4]. MALAT1 regulates cell
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Fig. 7 A schematic diagram depicting the mechanism of MALAT1 mediated regulation of inflammation in the endothelium in hyperglycaemia.
Hyperglycaemia initiates the inflammatory response cascade through
MALAT1 mediated up-regulation of serum amyloid antigen, thus stimulating the induction of inflammatory markers IL-6 and TNF-a. IL-6 and
TNF-a can then maintain a sustained endothelial inflammation which
sets the stage for cardiovascular diseases especially under nutrient
stress.

survival through modulating p53 expression [5]. With respect to other
cytokines, MALAT1 has been shown to regulate TGFb signalling by
modulating activity of SMAD2/3 [15]. In addition, studies in MALAT1
knockout mice have shown SAA3 is regulated by MALAT1 and that
SAA3 stimulates IL-6 and TNF-a production through NFjB and p38
mitogen activated protein kinase signalling [4, 16]. Till to date there
has been no study revealing the signalling mechanisms associated
with MALAT1 induction and how it could play a role in hyperglycaemic stress. Interestingly, we found early increase followed by a drop
of MALAT1, which in turn positively up-regulate the inflammatory
ligand like SAA3, ultimately augmenting production of inflammatory
cytokines like IL-6 and TNF-a. However, this pattern is different than
the cancer cells where such expression levels remain high [5, 14].
Further duration-dependent studies at various stages of diabetes
using animal models (acute, short-term and long-term) would reveal
whether this lncRNA, MALAT1 is a real culprit as an initiator of inflam-

mation and oxidative stress. In keeping with such notion we have
shown that MALAT1, through SAA3, also regulates glucose-induced
inflammatory changes and oxidative stress. Such changes may influence endothelial stability. Endothelial homeostasis is essential for all
organs and for macro and micro vessels. If we understand the
switches involved in early endothelial inflammatory process, we may
be able to retard the progress and consequences of such damage.
In summary, in this study, we revealed a novel signalling
nexus involving the lncRNA, MALAT1 and SAA3 which then turns
on the inflammatory mediators in the endothelium as shown in
the summary diagram (Fig. 7). Understanding such mechanisms
may eventually lead to novel RNA based therapeutic strategies
for diabetic induced micro- and macro vascular complications.
However, it is to be noted that the demonstrated role of MALAT1-SAA–Cytokine needs further evaluation in well-designed animal experiments with long-term diabetes. Such experiments may
show whether MALAT1 may lend itself as a possible drug target
in chronic diabetic complications.

Acknowledgements
This work was supported by funding from the Canadian Diabetes Association
and the Heart and Stroke Foundation of Ontario to Dr. Subrata Chakrabarti. PP
researched the data, wrote the manuscript analysed the data and contributed
to the discussion. SC, AG and BF researched the data and contributed to the
discussion. SC is the guarantor of this work, and maintained the integrity and
accuracy of data and also contributed towards data analysis and manuscript
writing.

Disclosure
All the authors confirm that there are no conflicts of interest.

References
1.

2.

3.

4.

5.

1424

Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009; 120: 1266–86.
Tabit CE, Chung WB, Hamburg NM, et al.
Endothelial dysfunction in diabetes mellitus:
molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010; 11:
61–74.
Berg AH, Scherer PH. Adipose tissue,
inflammation, and cardiovascular disease.
Circulation Res. 2005; 96: 939–49.
Zhang B, Arun G, Mao YS, et al. The lncRNA
Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2012; 2: 111–
23.
Tripathi V, Shen Z, Chakraborty A, et al.
Long noncoding RNA MALAT1 controls cell
cycle progression by regulating the expres-

6.

7.

8.

9.

sion of oncogenic transcription factor
B-MYB. PLoS Genet. 2013; 9: 1–18.
Doi:10.1371/journal.pgen.10033682013.
Guo F, Li Y, Liu Y, et al. Inhibition of metastasis-associated lung adenocarcinoma
transcript 1 in CaSki human cervical cancer
cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin. 2010; 42:
224–9.
Gutschner T, H€ammerle M, Diederichs S.
MALAT1 – a paradigm for long noncoding
RNA function in cancer. J Mol Med. 2013;
91: 791–801.
Yan B, Tao ZF, Li XM, et al. Aberrant
expression of long noncoding RNAs in early
diabetic retinopathy. Invest Ophthalmol Vis
Sci. 2014; 55: 941–51.
Han CY, Subramanian S, Chan CK, et al.
Adipocyte-derived serum amyloid A3 and

10.

11.

12.

13.

hyaluronan play a role in monocyte recruitment and adhesion. Diabetes. 2007; 56:
2260–73.
Larson MA, Wei SH, Weber A, et al. Induction of human mammary-associated serum
amyloid A3 expression by prolactin or lipopolysaccharide. Biochem Biophys Res Commun. 2003; 301: 1030–7.
Giacco F, Brownlee M. Oxidative stress and
diabetic complications. Circ Res. 2010; 107:
1058–70.
Kern TS. Contributions of inflammatory processes to the development of the early
stages of diabetic retinopathy. Exp Diab Res.
2007; Doi:10.1155/2007/95103.
Wahlestedt C. Targeting long non-coding
RNA to therapeutically upregulate gene
expression. Nat Rev Drug Discov. 2013; 12:
433–46.

ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

J. Cell. Mol. Med. Vol 19, No 6, 2015
14.

Hackerm€uller J, Reiche K, Otto C, et al. Cell
cycle, oncogenic and tumor suppressor
pathways regulate numerous long and
macro non-protein coding RNAs. Genome
Biol. 2014; 15: R48–58.

15.

Watts R, Johnsen VL, Shearer J, et al.
Myostatin-induced inhibition of the long
noncoding RNA Malat1 is associated with
decreased myogenesis. Am J Physiol Cell
Physiol. 2013; 304: C995–1001.

16.

Deguchi A, Tomita T, Omori T, et al.
Serum amyloid A3 binds MD-2 to activate
p38 and NF-jB pathways in a MyD88dependent manner. J Immunol. 2013; 191:
1856–64.

ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

1425

